New hope for tough lung cancer: SYS6010 takes on chemo in phase 3 trial
NCT ID NCT07442565
First seen Mar 03, 2026 · Last updated Jun 09, 2026 · Updated 14 times
Summary
This study compares a new experimental drug, SYS6010, to a standard chemotherapy drug (docetaxel) in people with a specific type of advanced lung cancer (non-squamous non-small cell) that no longer responds to other treatments. The goal is to see if SYS6010 can help people live longer without their cancer growing. About 506 participants will be randomly assigned to receive either SYS6010 or docetaxel.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.